iRadimed (NASDAQ:IRMD) Stock Passes Above Fifty Day Moving Average – Should You Sell?

iRadimed Corporation (NASDAQ:IRMD) shares passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $90.92 and traded as high as $96.74. iRadimed shares last traded at $96.42, with a volume of 154,713 shares changing hands.

Analyst Ratings Changes

Several research analysts have weighed in on IRMD shares. Roth Mkm reiterated a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research report on Tuesday, February 10th. Weiss Ratings cut shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 20th. Freedom Capital upgraded shares of iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Finally, Lake Street Capital reaffirmed a “buy” rating and set a $120.00 price target on shares of iRadimed in a research report on Wednesday, February 11th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $120.00.

iRadimed Stock Up 2.2%

The firm has a market capitalization of $1.23 billion, a P/E ratio of 52.69 and a beta of 0.91. The firm has a 50 day moving average of $90.92 and a 200-day moving average of $95.78.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.03. The firm had revenue of $21.98 million for the quarter, compared to analyst estimates of $21.32 million. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. As a group, research analysts expect that iRadimed Corporation will post 1.52 EPS for the current year.

iRadimed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, May 29th. Investors of record on Friday, May 15th were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. iRadimed’s payout ratio is 43.72%.

Insiders Place Their Bets

In other iRadimed news, CEO Roger E. Susi sold 2,500 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $90.60, for a total transaction of $226,500.00. Following the sale, the chief executive officer directly owned 2,162,500 shares in the company, valued at $195,922,500. This represents a 0.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 62,500 shares of company stock worth $5,794,878 over the last three months. Corporate insiders own 36.80% of the company’s stock.

Institutional Trading of iRadimed

A number of institutional investors and hedge funds have recently made changes to their positions in IRMD. CWM LLC increased its stake in iRadimed by 19.5% in the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock valued at $64,000 after acquiring an additional 107 shares during the last quarter. Johnson Investment Counsel Inc. lifted its stake in iRadimed by 0.7% during the third quarter. Johnson Investment Counsel Inc. now owns 25,842 shares of the medical equipment provider’s stock worth $1,839,000 after purchasing an additional 187 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of iRadimed by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock valued at $252,000 after purchasing an additional 234 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of iRadimed by 4.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,824 shares of the medical equipment provider’s stock valued at $567,000 after purchasing an additional 267 shares in the last quarter. Finally, Quantinno Capital Management LP increased its stake in shares of iRadimed by 12.5% in the 1st quarter. Quantinno Capital Management LP now owns 3,482 shares of the medical equipment provider’s stock valued at $335,000 after purchasing an additional 387 shares during the last quarter. Institutional investors own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.